AstraZeneca mulls risk strategy for Ultomiris following FDA response letter
The US FDA has requested that AstraZeneca make modifications to the Ultomiris REMS programme to approve a label expansion.
The US FDA has requested that AstraZeneca make modifications to the Ultomiris REMS programme to approve a label expansion.
What's Your Reaction?
